An­oth­er warn­ing let­ter for Lupin as FDA iden­ti­fies de­fi­cien­cies at In­dia-based site

With few new de­tails of what needs fix­ing, Lupin dis­closed last week that the FDA re­cent­ly sent a warn­ing let­ter to its Tara­pur, In­dia-based site.

Af­ter an in­spec­tion from March 22 to April 4, Lupin dis­closed in an April stock fil­ing that it re­ceived a Form 483 with four ob­ser­va­tions, but it didn’t of­fer any de­tails on the ob­ser­va­tions.

Sim­i­lar to com­ments made in April, the com­pa­ny said last week it does not be­lieve the FDA slap will dis­rupt its drug sup­plies or the ex­ist­ing rev­enues from op­er­a­tions of this fa­cil­i­ty.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER